- Trial Phase
- Phase 2
- Time to Market
- Likely several years away. Phase 3 planning is underway but no trial has started as of late 2026. If Phase 3 begins in 2027, a potential approval would be at least 4-5 years out, assuming positive results.
- Why 3/10
- No hard, dated binary catalyst is scheduled in the next ~12 months. The Phase 2b LEVANTE study is completed but its results have not been formally released as topline, and Phase 3 planning was announced in April 2026 but no trial has started. Sunakiment is a small part of Amgen's large, diversified pipeline, so even a major readout would have limited impact on the stock.
Watch for formal disclosure of LEVANTE Phase 2b results, which could inform whether the drug advances to Phase 3. Also monitor for the start of Phase 3 enrollment, which would signal continued commitment from Amgen and AstraZeneca. Given Amgen's size and diversified pipeline, sunakiment is unlikely to be a standalone catalyst for the stock in the near term.
Price Chart
Executive Summary
Sunakiment (AMG 104 / AZD8630) is an inhaled anti-TSLP antibody fragment being developed by Amgen (AMGN) in collaboration with AstraZeneca for moderate-to-severe asthma. It targets the same protein as Amgen/AstraZeneca's blockbuster injected drug Tezspire (tezepelumab) but is delivered via a dry-powder inhaler directly to the lungs. Phase 1 data published in 2026 showed proof-of-mechanism with a statistically significant reduction in airway inflammation. The Phase 2b LEVANTE dose-ranging study completed in February 2026 with encouraging results, and Phase 3 planning is underway. However, sunakiment is a small part of Amgen's massive pipeline, no near-term binary catalyst exists, and the inhaled TSLP space faces competition from Novartis's ecleralimab.
How It Works
Sunakiment is an inhaled antibody fragment that blocks thymic stromal lymphopoietin (TSLP), a protein released by cells lining the airways that acts as an early alarm signal to trigger inflammation in asthma. By neutralizing TSLP directly in the lungs via a dry-powder inhaler, it aims to stop the inflammatory cascade before it starts, similar to the injected drug Tezspire (tezepelumab) but delivered locally rather than through the bloodstream.
Trial Status
A Phase 1 first-in-human study (NCT05110976) was completed and published in The Journal of Allergy and Clinical Immunology in 2026, demonstrating acceptable safety, dose-dependent pharmacokinetics, and proof-of-mechanism with a statistically significant 23% reduction in FeNO (a biomarker of airway inflammation) at the 8 mg dose versus placebo (P=.037). The Phase 2b LEVANTE dose-ranging study (NCT06529419) in adults with uncontrolled asthma at risk of exacerbations completed in February 2026. Synapse describes the results as "encouraging and informative for dose selection," though no formal topline press release has been issued. As of April 2026, Amgen and AstraZeneca were planning a Phase 3 development program in asthma.
The Two-Sided Case
Upcoming Catalysts
- Formal disclosure of LEVANTE Phase 2b topline results (completed Feb 2026, results not yet publicly released in detail)
- Initiation of Phase 3 program in asthma (planning announced April 2026)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Amgen PRESS-RELEASE AMGN ·Originating report